Business
Grant of Options under Long Term Incentive Plan
Grant of Options under Long Term Incentive Plan.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 9019R Allergy Therapeutics PLC 11 March 2016 \n\n \n \n \n11 March 2015\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \nGrant of Options under Long Term Incentive Plan \n \nAllergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today confirms that certain performance conditions attaching to provisional awards (\"Awards\") made pursuant to the Company's Long Term Incentive Plan (\"LTIP\") for the three years ended 8 March 2015, details of which were announced on 15 May 2013, have been met. Consequently, Allergy Therapeutics has today granted certain of its directors low cost options (\"Options\") over the Company's ordinary shares of 0.1 pence each (\"Ordinary Shares\") in replacement for the Awards made under the LTIP as follows:\n\n\n\n\nDirector\n\n\nNumber of Ordinary Shares over which Options granted\n\n\nTotal number of Ordinary Shares over which Options granted \n\n\nTotal remaining number of Ordinary Shares provisionally awarded under LTIPs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nManuel Llobet,\nChief Executive Officer\n\n\n905,000\n\n\n1,529,024\n\n\n 1,690,000\n\n\n\n\nIan Postlethwaite,\nFinance Director\n\n\n452,500\n\n\n928,012\n\n\n845,000\n\n\n\n\n \nThe Options have been granted in accordance with the LTIP rules and can be exercisable between 11 March 2016 and 11 March 2026 at an exercise price of 0.1p per Ordinary Share.\n\n\n\n\n\n\n\n\n\n\n\n\nFor further information please contact:\n \nAllergy Therapeutics\n+44 (0) 1903 845 820\nManuel Llobet, Chief Executive Officer\nIan Postlethwaite, Finance Director\n \nPanmure Gordon\n+44 (0) 20 7886 2500\nFreddy Crossley / Duncan Monteith, Corporate Finance\nTom Salvesen, Corporate Broking\n \nConsilium Strategic Communications\n+44 20 3709 5700\nMary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton\[email protected]\n \nNote to editors:\n \nAbout Allergy Therapeutics\nAllergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its s...